Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study
Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study
复制标题
DOI：
10.3899/jrheum.111549
复制
发表时间：
2012-10-01
影响因子：
3.9
通讯作者：
Pettersson, Tom
中科院分区：
文献类型：
--
作者：
Nordstrom, Dan;Knight, Ann;Pettersson, Tom
Objective.研究阿那白滞素与改善疾病的抗风湿药物（DMARD）治疗难治性成人斯蒂尔病（AOSD）的疗效。方法。在一项为期24周的研究中，22名服用泼尼松龙≥ 10 mg/天的AOSD患者接受阿那白滞素（n = 12）或DMARD（n = 10）治疗。主要终点是达到缓解。在第8周和第24周，接受阿那白滞素治疗的7/12和6/12例患者以及接受DMARD治疗的5/10和2/10例患者获得缓解。阿那白滞素诱导身体健康的更大改善，通过医学结局研究简表36（SF-36; p < 0.011）测量。在为期28周的开放标签扩展期（OLE）中，7/14例服用阿那白滞素的患者和2/3例服用DMARD的患者缓解。在AOSD患者中，阿那白滞素比DMARD诱导更多的有益反应，并且在OLE期更受欢迎。（ClinicalTrials.gov方案注册NCT 01033656）。（2012年8月1日首次发布; J Rheumol 2012;39：2008-11; doi：10.3899/jrheum.111549）
Objective. To study the efficacy of anakinra versus disease-modifying antirheumatic drugs (DMARD) in refractory adult-onset Still's disease (AOSD).Methods. In a 24-week study, 22 patients with AOSD taking prednisolone >= 10 mg/day received anakinra (n = 12) or DMARD (n = 10). The primary endpoint was achievement of remission.Results. At 8 and 24 weeks, 7/12 and 6/12 receiving anakinra and 5/10 and 2/10 receiving DMARD achieved remission. Anakinra induced greater improvement in physical health measured by Medical Outcomes Study Short-Form 36 (SF-36; p < 0.011). During an open-label extension (OLE) of 28 weeks, 7/14 patients taking anakinra and 2/3 taking DMARD were in remission.Conclusion. Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the OLE phase. (ClinicalTrials.gov Protocol Registration NCT01033656). (First Release Aug 1 2012; J Rheumatol 2012;39:2008-11; doi:10.3899/jrheum.111549)